



3-26-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige et al.

Serial No.: 10/645,784

Group Art Unit No.: 1642

Filed: August 18, 2003

Examiner: S. Huff

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527E

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy J. Gault
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: March 23, 2004

Please send all future correspondence to:
US Patent Operations/ [TJG]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EV351338285US

Date of Deposit: March 24, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SL ST. ANDREW
Printed Name

SL ST. ANDREW
Signature

Modified Form PTO-1449

Atty. Docket No.

A-527E

Serial No.	
------------	--

10/645.784

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Feige et al.

Filing Date

August 18, 2003

Group

1642

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449	Atty. Docket No.	Serial No.
	A-527E	10/645.784
	Applicant	
	Feige et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Filing Date	Group
	August 18, 2003	1642

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CIB. CLASS	TRANSLATION	
							YES	NO
	B1✓	WO 02/16412	02/28/02	PCT				
	B2✓	WO 02/16411	02/28/02	PCT				
	B3✓	WO 01/85782	11/15/01	PCT				
	B4✓	WO 01/02440	01/11/01	PCT				
	B5✓	WO 00/68378	11/16/00	PCT				
	B6✓	WO 00/67034	11/09/00	PCT				
	B7✓	WO 00/47740	08/17/00	PCT				
	B8✓	WO 00/40716	07/13/00	PCT				
	B9✓	WO 00/24782	05/04/00	PCT				
	B10✓	WO 99/35170	07/15/99	PCT				
	B11✓	WO 99/25044	05/20/99	PCT				
	B12✓	WO99/12964	03/18/99	PCT				
	B13✓	WO 99/11791	03/11/99	PCT				
	B14✓	WO 98/55620	12/10/98	PCT				
	B15✓	WO 98/55621	12/10/98	PCT				
	B16✓	WO 98/27114	06/25/98	PCT				
	B17✓	WO 98/18921	05/07/98	PCT				
	B18✓	WO 98/15833	04/16/98	PCT				
	B19✓	WO 96/40987	12/19/96	PCT				
	B20✓	EP 0 869 180	10/07/98	Hurle et al.				
	B21✓	EP 0 526 452	02/21/01	Capon et al.				

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-527E	10/645.784
	Applicant	
	Feige et al.	
	Filing Date	Group
	August 18, 2003	1642

EXAMINER'S INITIALS	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	C1 ✓	Cwirla et al. (1997), "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <i>Science</i> 276: 1696-1699.
	C2 ✓	Devlin et al. (1990), "Random Peptide Libraries: A Source of Specific Protein Binding Molecules," <i>Science</i> 249: 404-406.
	C3 ✓	Gross et al. (2000), "TACI and BCMA are Receptors for a TNF Homologue Implicated in B-cell Autoimmune Disease," <i>Nature</i> 404: 995-999.
	C4 ✓	Gruss et al. (1995), "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas," <i>Blood</i> 85(12): 3378-3404.
	C5 ✓	Hatzoglou et al. (2000), "TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF- κ B, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase," <i>J. of Immunology</i> 165: 1322-1330.
	C6 ✓	Khare et al. (2000), "Severe B Cell Hyperplasia and Autoimmune Disease in TALL-1 Transgenic Mice," <i>PNAS</i> 97(7):3370-3375.
	C7 ✓	Lowman (1997), "Bacteriophage Display and Discovery of Peptide Leads for Drug Development," <i>Ann. Rev. Biophys. Biomol. Struct.</i> 26: 401-424.
	C8 ✓	Roberts & Szostak (1997), "RNA-Peptide Fusions for the in vitro Selection of Peptides and Proteins," <i>Proc. Natl. Acad. Sci. USA</i> , 94: 12297-12302.
	C9 ✓	Shu et al. (1999), "TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens," <i>J. Leukocyte Biol.</i> 65:680-683.
	C10 ✓	Shu et al. (2000), "B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1," <i>PNAS</i> 97(16):9156-9161.
	C11 ✓	Smith et al. (1994), "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death," <i>Cell</i> 76: 959-962.
	C12 ✓	Takasaki et al. (1997), "Structure-based Design and Characterization of Exocyclic Peptidomimetics that Inhibit TNF α Binding to its Receptor," <i>Nature Biotech.</i> 15: 1266-1270.
	C13 ✓	Thompson et al. (2000), "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population," <i>J. Exp. Med.</i> 192(1):129-135.
	C14 ✓	Ware (2000), "APRIL and BAFF Connect Autoimmunity and Cancer," <i>J. Exp. Med.</i> 192(11): F35-F37.
	C15 ✓	Ware (2000), "Decoy Receptors Thwart B Cells," <i>Nature</i> 404: 949-950.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-527E	10/645.784
	Applicant	
	Feige et al.	
	Filing Date	Group
	August 18, 2003	1642

EXAMINER'S
INITIALS**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C16 ✓	Xia et al. (2000), "TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation," <i>J. Exp. Med.</i> 192(1):137-143.
C17 ✓	Yu et al. (2000), "APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity," <i>Nature Immunology</i> 1(3):252-256.
C18 ✓	Tan et al. (2002), "Local Production of B Lymphocyte Stimulator (BlyS™) Protein in Human Arthritic Joints," <i>abstract</i> .
C19 ✓	Cheema et al. (2002), "Increased B Lymphocyte Stimulator (BlyS™) Protein in HIV-Patients: Correlation with Anti-Cardiolipin (aCL) and Anti-Phospholipid (aPL) Autoantibodies," <i>abstract</i> .
C20 ✓	Sekut et al. (2002), "Characterization of a Human Monoclonal Antibody that Antagonizes B-Lymphocyte Stimulator Bioactivities," <i>abstract</i> .
C21 ✓	Zhang et al. (2001), "Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus," <i>J. Immunology</i> 166:6-10.
C22 ✓	Oren et al. (2002), "Structural Basis of BlyS Receptor Recognition," <i>Nature Structural Biology</i> 9(4): 288-292.
C23 ✓	Cheema et al. (2001), "Elevated Serum B Lymphocyte Stimulator Levels in Patients With Systemic Immune--Based Rheumatic Diseases," <i>Arthritis & Rheumatism</i> 44(6):1313-1319.
C24 ✓	Mukhopadhyay et al. (1999), "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor- κ B, and c-June NH ₂ Terminal Kinase," <i>J. Biol. Chem.</i> 274(23): 15978-15981.
C25 ✓	Marsters et al. (2000), "Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI," <i>Current Biology</i> 10(13):785-788.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.